359 related articles for article (PubMed ID: 12117418)
1. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
2. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
3. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
4. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
5. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
[TBL] [Abstract][Full Text] [Related]
7. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
Piro O; Broze GJ
Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
[TBL] [Abstract][Full Text] [Related]
8. Tissue factor pathway inhibitor; its structure, function and clinical significance.
Kato H
Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
[TBL] [Abstract][Full Text] [Related]
9. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
Lockett JM; Mast AE
Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
11. Effect of leukocyte proteinases on tissue factor pathway inhibitor.
Petersen LC; Bjørn SE; Nordfang O
Thromb Haemost; 1992 May; 67(5):537-41. PubMed ID: 1519213
[TBL] [Abstract][Full Text] [Related]
12. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
13. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
Li A; Chang AC; Peer GT; Wun TC; Taylor FB
Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
[TBL] [Abstract][Full Text] [Related]
14. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes.
Willems GM; Janssen MP; Salemink I; Wun TC; Lindhout T
Biochemistry; 1998 Mar; 37(10):3321-8. PubMed ID: 9521652
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
16. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene.
Chang JY; Monroe DM; Oliver JA; Roberts HR
Thromb Haemost; 1999 Jan; 81(1):45-9. PubMed ID: 9974373
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T
Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224
[TBL] [Abstract][Full Text] [Related]
18. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity.
Li A; Wun TC
Thromb Haemost; 1998 Sep; 80(3):423-7. PubMed ID: 9759622
[TBL] [Abstract][Full Text] [Related]
20. The effect of leukocyte elastase on tissue factor pathway inhibitor.
Higuchi DA; Wun TC; Likert KM; Broze GJ
Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
